Related Experiment Videos
Platelet-activating factor-mediated contraction of rabbit lung strips: pharmacologic modulation
Immunopharmacology
|August 1, 1983
Summary
Synthetic platelet-activating factor (PAF) causes lung contractions by activating specific receptors. Its effects are blocked by inhibiting certain enzymes and calcium channels, suggesting therapeutic targets for lung conditions.
Area of Science:
- Pharmacology
- Respiratory Physiology
- Cell Signaling
Background:
- Platelet-activating factor (PAF) is a lipid mediator implicated in inflammatory and allergic responses.
- Synthetic PAF, specifically 1-0-octadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (AGEPC), is used to study PAF receptor interactions.
- Lung parenchymal strips are a standard model for investigating airway smooth muscle contraction.
Purpose of the Study:
- To characterize the mechanism of contraction induced by synthetic platelet-activating factor (AGEPC) in rabbit lung parenchymal strips.
- To identify the specific receptors and signaling pathways involved in AGEPC-mediated bronchospasm.
- To explore potential pharmacological interventions for AGEPC-induced lung contraction.
Main Methods:
- Isolated organ bath studies using rabbit lung parenchymal strips.
- Exposure to synthetic platelet-activating factor (AGEPC) to assess contractile responses.
- Pharmacological profiling using receptor antagonists, enzyme inhibitors (cyclooxygenase, phospholipase A2, lipoxygenase), calcium channel blockers, and corticosteroids.
- Measurement of intracellular cyclic AMP and cyclic GMP levels.
Main Results:
- Synthetic PAF (AGEPC) induced a slow, sustained contraction of rabbit lung parenchymal strips.
- The AGEPC-induced contraction involved specific receptors distinct from histamine, cholinergic, and C5a receptors.
- Contraction was dependent on phospholipase A2 and lipoxygenase activity, calcium influx, and modulated by cyclic nucleotides.
- Corticosteroids demonstrated a specific inhibitory effect on AGEPC-induced contraction.
Conclusions:
- Synthetic PAF (AGEPC) mediates bronchoconstriction through a distinct receptor pathway involving phospholipase A2, lipoxygenase, and calcium channels.
- Specific desensitization to AGEPC occurs after prior exposure.
- The findings suggest potential therapeutic strategies targeting these pathways for PAF-related lung pathologies.